Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

(2011) O. L. Chinot et al.   ADVANCES IN THERAPY

Quantitative analysis of matrix metalloproteinase-2 mRNA expression in central and peripheral regions of gliomas

(2011) Marta Brell et al.   Brain Tumor Pathology

Matrix metalloproteinase 2 attenuates brain tumour growth, while promoting macrophage recruitment and vascular repair

(2011) Pierrot Tremblay et al.   JOURNAL OF PATHOLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

(2011) J. F. de Groot et al.   NEURO-ONCOLOGY

Vascular Endothelial Growth Factor in the Circulation in Cancer Patients May Not Be a Relevant Biomarker

(2011) Tatjana M. H. Niers et al.   PLoS One

Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity

(2010) Shingo Takano et al.   Brain Tumor Pathology

A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas

(2010) Jeffrey J. Raizer et al.   CANCER

Bevacizumab: current updates in treatment

(2010) Margaret EM Van Meter et al.   CURRENT OPINION IN ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

(2010) Adrian M Jubb et al.   LANCET ONCOLOGY

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab

(2010) M. Prados et al.   NEURO-ONCOLOGY

High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas

(2009) Carole Colin et al.   ACTA NEUROPATHOLOGICA

Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy

(2009) A. K. Lucio-Eterovic et al.   CLINICAL CANCER RESEARCH

Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer

(2009) Roopali Roy et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non–Small-Cell Lung Cancer

(2009) Emer O. Hanrahan et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?

(2009) Dan G. Duda et al.   JOURNAL OF CLINICAL ONCOLOGY

Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy

(2008) E. R. Smith et al.   CLINICAL CANCER RESEARCH

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

(2008) Sith Sathornsumetee et al.   JOURNAL OF CLINICAL ONCOLOGY

Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM

(2008) Rose Du et al.   NEURO-ONCOLOGY